Letrozol Devatis 2,5 mg

Description

Indications

• Adjuvant treatment of hormone-positive early breast cancer in postmenopausal women.
• Advanced adjuvant therapy of early breast cancer in postmenopausal women who have received standard adjuvant therapy with tamoxifen.
• Treatment of advanced breast cancer in postmenopausal women as first-line treatment.
• Treatment of advanced breast cancer in postmenopausal women in case of disease progression after previous treatment with tamoxifen or other anti-estrogens.
• Neoadjuvant treatment of postmenopausal women with localised hormone-positive breast cancer, which offers the possibility of further surgical treatment, for surgical treatment was not indicated. Further therapy after surgical treatment should follow accepted standards for the postoperative period.

Contraindications

• Hypersensitivity to the active substance or any other component of the drug.
• Endocrine condition characteristic of the premenopausal period.
• Severe hepatic insufficiency (Child-Pugh class C).
• Preoperative use of the drug if the receptor status is negative or unknown.

Method of administration and dosage

Adults and elderly patients. The recommended dose of Leterrier is 2.5 mg once daily. In adjuvant treatment, treatment with Leterrier should be continued for 5 years or until relapse. After standard adjuvant treatment with tamoxifen, observation and treatment with Leterrier should be continued for 5 years or until disease recurrence. In patients with metastatic disease, treatment with Leterrier should be continued until there are signs of disease progression. Continuous monitoring during pre-operative preparation is recommended. No dose adjustment is required in elderly patients.

Patients with hepatic and/or renal impairment. No dose adjustment is required in patients with mild to moderate hepatic impairment (Child-Pugh class A and B) or renal impairment (creatinine clearance ≥ 10 ml/min).